Alpha-GPC: What it is, how to dose it, what effect it has on the brain
Alpha-GPC is one of the few compounds in the nootropic category about which something rare can be said: it has an established, dual regulatory status.
Alpha-GPC is one of the few compounds in the nootropic category about which something rare can be said: it has an established, dual regulatory status. It appears simultaneously as a food ingredient assessed by EFSA and as an active substance in a registered medicinal product. This duality explains much of the confusion surrounding it – including the repeated claim that it “helps treat Alzheimer’s disease.” The research behind this claim does exist, but it only concerns the second identity, not the supplement.
This article describes the cholinergic mechanism in depth, compares Alpha-GPC to citicoline, and sorts out the legal status. It does not contain dosage or combination regimens.
Note on the framing of this text. Alpha-GPC is not a research reagent or unauthorized substance – it is a food ingredient with an assessed status. We describe it according to this category. A broader map of the legal status of the entire nootropic category is included in our material about nootropic substances.
What is Alpha-GPC
Alpha-GPC, or L-alpha-glycerylphosphorylcholine, is a naturally occurring compound made of a choline molecule combined with glycerophosphate. In the body, it is an element of the phospholipid metabolism of cell membranes – it is an endogenous metabolite, not a foreign substance. It occurs in small amounts in food, including milk and milk products and offal.
Chemically, two features are important. The molecule is water-soluble, yet contains about half its mass as choline – making it one of the denser sources of this nutrient. In the pharmaceutical literature it is known as choline alfoscerate and this name appears in drug registration documentation.
Mechanism – from precursor to neurotransmitter
The action of Alpha-GPC is based on its role as a precursor, which distinguishes it from several other approaches used in this category. It is worth following this path step by step, because it presents both opportunities and limitations.
Step one – choline supply. Acetylcholine is produced in nerve endings from two substrates: choline and acetyl-coenzyme A. Choline is not synthesized in neurons in quantities covering the demand, so it must be supplied from the blood. This is the bottleneck of the entire process.
Step two – crossing the blood-brain barrier. Not every form of choline overcomes this barrier equally efficiently. Alpha-GPC is described as a form that penetrates well into the central nervous system, where it is broken down with the release of free choline.
Step three – neurotransmitter synthesis. The released choline is used by choline acetyltransferase to synthesize acetylcholine – a neurotransmitter involved in coding the memory trace, maintaining attention and transmitting at the neuromuscular junction. This last thread explains why the relationship was also studied in the context of exercise.
The profile of choline as an ingredient and the differences between its forms are discussed in the review devoted to supplementation with this ingredient (Kansakar et al., 2023, PMID 36950691), and the compound itself – in the review devoted to choline alfoscerate as a substance with a cognitive profile (Traini et al., 2013, PMID 24156263).
Interactions beyond the cholinergic system have also been described: work from the 1980s examined the effect of L-alpha-glycerylphosphorylcholine on the relationship between cholinergic and dopaminergic neurons in the central nervous system (Trabucchi et al., 1986, PMID 3709792). This is a preclinical observation and should be read as such – it does not constitute the basis for claims about the impact on motivation or mood in humans.
Limitation of a mechanism that is rarely written about: providing a substrate increases the availability of material for synthesis, but does not itself increase the activity of cholinergic neurons. If the system is not limited by the availability of choline, its additional supply does not necessarily translate into a change in function. This is one of the hypotheses explaining why the results tend to be more pronounced in populations with reduced cholinergic function than in healthy people.
Alpha-GPC and citicoline – two routes to the same molecule
Citicoline (CDP-choline) is the second commonly used choline precursor and the most common reference point. Both compounds lead to an increase in choline availability, but are not interchangeable.
| Alpha-GPC | Citicoline (CDP-choline) | |
|---|---|---|
| Construction | choline + glycerophosphate | cytidine + diphosphate + choline |
| Decomposition products | choline, glycerophosphate | choline and cytidine (converted into uridine in humans) |
| Choline content | higher on a mass basis | lower on a mass basis |
| Additional mechanistic thread | none – works through choline itself | uridine component associated with the synthesis of membrane phospholipids |
The fundamental difference lies in the last line: citicoline contributes a second substrate, which Alpha-GPC does not provide. The pharmacology and clinical applications of citicoline are summarized in a comprehensive review (Secades and Gareri, 2022, PMID 36544369), and its effectiveness in preventing and slowing dementia was assessed in a systematic review with meta-analysis (Bonvicini et al., 2023, PMID 36678257). This does not mean that one compound is superior to the other – it means that they were studied in different contexts and the results do not transfer between them.
Both forms were compared directly in a study in healthy volunteers, which compared concentrations of free choline in plasma after intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline (Gatti et al., 1992, PMID 1428296). However, this is a pharmacokinetic comparison – it speaks about the availability of choline, not about cognitive or performance results. There are no studies comparing both forms in terms of functional effect in the same population.
Dual regulatory status
This is the essence of the article and at the same time the source of the most common error in the descriptions of Alpha-GPC.
As a food ingredient
The EFSA Panel on Nutrition, Novel Foods and Food Allergens assessed L-alpha-glycerylphosphorylcholine as a novel food within the meaning of Regulation (EU) 2015/2283 and concluded that it is safe under the proposed conditions of use. These conditions include a maximum use level in food supplements of 203.7 mg per day, equivalent to 82.5 mg of choline per day, for the population over 3 years of age, excluding supplements for infants and young children (EFSA NDA Panel, 2026, DOI 10.2903/j.efsa.2026.10008).
As the active substance of the medicinal product
Choline alfoscerate is the active ingredient in the preparations Gliatilin® and Delecit® — medicinal products authorized for marketing at national level in some countries, used in cognitive, memory and attention disorders in the elderly. In this application, use levels reach 1000 mg per day, multiples of the level assessed for food (data cited in the cited EFSA opinion).
Why this distinction matters
Both numbers above are regulatory reference points, not recommendations. We mention them only to show the scale of the difference – and the difference is almost fivefold. This leads to the following conclusion:
The claim “Alpha-GPC helps treat Alzheimer’s disease” is an invalid shorthand, but that’s not because the relevant research doesn’t exist. These studies exist, but they were conducted on a medicinal product, in a population with the diagnosis, and at drug-specific levels. Transferring their conclusions to a food supplement used by a healthy person is changing three variables at once: the formulation, the population, and the level of use. A food supplement does not cure disease and cannot be described as such — regardless of what has been shown for a drug with the same active ingredient.
What the research shows — and in what context
Clinical populations
The most frequently cited study is a multicenter, double-blind, randomized, placebo-controlled trial that evaluated choline alfoscerate in people with mild to moderate Alzheimer’s dementia (De Jesus Moreno Moreno, 2003, PMID 12637119). This is a study in a therapeutic context, not a nutritional one.
The totality of available evidence for adult-onset cognitive impairment is summarized in a systematic review with meta-analysis (Sagaro et al., 2023, PMID 36683513) — the highest level of evidence available for this association. The combination of choline alfoscerate with donepezil was also studied (Lee and Kim, 2024, PMID 38875437) and its impact on cognitive functions and quality of life in people with type 2 diabetes (Sohn et al., 2025, PMID 39703111).
Healthy people
This group of data is much more modest, but it exists – and this distinguishes Alpha-GPC from most compounds described in the nootropic category.
- Cognitive functions. The randomized study assessed the effect of a single administration of Alpha-GPC on the performance of cognitive tasks in healthy men (Kerksick, 2024, PMID 39683633).
- Physical and psychomotor performance. The effect of two levels of Alpha-GPC on parameters of physical and psychomotor performance was assessed (Marcus et al., 2017, PMID 29042830) — this is a thread related to the role of acetylcholine in the neuromuscular junction.
- In a multi-component formula. A randomized crossover study evaluated Alpha-GPC combined with branched chain amino acids and L-citrulline in training cyclists (Harrington, 2023, PMID 37229544). In such a design, it is not possible to attribute the observed result to a single ingredient.
What the data do not show
- The data do not show the therapeutic effect of a food supplement. Medicinal context data relates to the medicinal product, the diagnosis population, and other levels of use.
- The data do not show a cumulative effect in healthy individuals. Available studies in this group mainly concern single administration and narrow sets of tasks.
- The data do not show superiority over citicoline or vice versa. Both forms were compared directly in volunteers, but the comparison concerned free choline concentrations in plasma, not cognitive or performance results (PMID 1428296). Studies comparing them in terms of functional effect in the same population are lacking.
- The data do not show outcomes outside the assessed conditions of use. The EFSA assessment is for a specific level and a specific population; outside this range there is no rating to refer to.
Alpha-GPC as a component of compound formulas
Alpha-GPC is sometimes combined with racetams – because compounds of this group have been described as increasing choline utilization. However, it should be noted that something gets lost in such lists: racetams and Alpha-GPC belong to different regulatory groups. Alpha-GPC has an assessed status as a food ingredient, while phenylpiracetam and aniracetam do not have such status. We discuss this contrast in detail in the material about formula combining phenylpiracetam, aniracetam and Alpha-GPC.
Frequently asked questions
Does Alpha-GPC treat Alzheimer’s disease?
No. Studies in this indication were conducted on choline alfoscerate as a medicinal product, in people with the diagnosis and at use levels appropriate for the drug. A food supplement does not cure disease and cannot be described as such, regardless of the results obtained for a drug with the same active ingredient.
Is Alpha-GPC legal in the European Union?
Yes. The EFSA Panel assessed L-alpha-glycerylphosphorylcholine as a novel food and found it safe under the proposed conditions of use, which include a defined maximum level in food supplements for the population over 3 years of age.
What is the difference between Alpha-GPC and citicoline?
Both compounds are choline precursors, but citicoline additionally releases the cytidine component, which is converted into uridine in humans and associated with the synthesis of membrane phospholipids. Alpha-GPC works solely through choline itself, but has a higher choline content by weight.
Is Alpha-GPC on the WADA Prohibited List?
Alpha-GPC is not listed by name on the Prohibited List. However, the general clause should be kept in mind, covering substances with a similar structure or similar effect, and the current status should be verified each time in the current version of the List.
Why does the article not provide the dosage?
Because the conditions for the use of a food ingredient result from its approval and labeling of a specific product, not from the list in the article. The levels quoted in the text are regulatory reference points – they serve to show the difference between the food and medicinal framework, they are not a recommendation.
Summary
Alpha-GPC, or L-alpha-glycerylphosphorylcholine, is a choline precursor used for the synthesis of acetylcholine – a neurotransmitter involved in memory processes, maintaining attention and neuromuscular transmission. The mechanism involves the supply of a substrate, which also means its limitation: the supply of material does not by itself increase the activity of the cholinergic system if it was not limited by the availability of choline. The compound has dual regulatory status – as a novel food assessed by EFSA and found to be safe under certain conditions of use, and as an active ingredient in nationally authorized medicinal products, where use levels are nearly five times higher. This distinction results in the most important correction to common descriptions: Alzheimer’s disease studies focused on the drug, the diagnosed population and therapeutic levels, and their conclusions cannot be transferred to a food supplement used by a healthy person. In healthy people, there is data, but it is modest and mainly concerns single administration.
Product documentation
Product cards containing Alpha-GPC are available in the category advanced nootropics. Conditions of use are determined by the labeling of a specific product.
Bibliography
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of L-alpha-glycerylphosphorylcholine (L-alpha-GPC) from soya phospholipids (lecithin) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. 2026. DOI: 10.2903/j.efsa.2026.10008
- Sagaro GG, Traini E, Amenta F. Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2023;92(1):59-70. PMID: 36683513
- De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178-193. PMID: 12637119
- Lee W, Kim M. Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial. Medicine (Baltimore). 2024;103(24):e38067. PMID: 38875437
- Sohn M, Park YH, Lim S. Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab. 2025;27(3):1350-1358. PMID: 39703111
- Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients. 2024;16(23):4240. PMID: 39683633
- Marcus L, Soileau J, Judge LW, Bellar D. Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. J Int Soc Sports Nutr. 2017;14:39. PMID: 29042830
- Harrington RN. Effects of branched chain amino acids, l-citrulline, and alpha-glycerylphosphorylcholine supplementation on exercise performance in trained cyclists: a randomized crossover trial. J Int Soc Sports Nutr. 2023;20(1):2214112. PMID: 37229544
- Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013;10(10):1070-1079. PMID: 24156263
- Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1992;30(9):331-335. PMID: 1428296
- Trabucchi M, Govoni S, Battaini F. Changes in the interaction between CNS cholinergic and dopaminergic neurons induced by L-alpha-glycerylphosphorylcholine, a cholinomimetic drug. Farmaco Sci. 1986;41(4):325-334. PMID: 3709792
- Kansakar U, Trimarco V, Mone P, Varzideh F, Lombardi A, Santulli G. Choline supplements: An update. Front Endocrinol (Lausanne). 2023;14:1148166. PMID: 36950691
- Secades JJ, Gareri P. Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 2022;75(s05):S1-S89. PMID: 36544369
- Bonvicini M, Travaglini S, Lelli D, Antonelli Incalzi R, Pedone C. Is Citicoline Effective in Preventing and Slowing Down Dementia? A Systematic Review and a Meta-Analysis. Nutrients. 2023;15(2):386. PMID: 36678257